Packaged Device Or Kit Patents (Class 435/810)
-
Patent number: 7709272Abstract: The present invention relates to a diagnostic method for the detection of small quantities of amniotic fluid in the vagina. More specifically, the invention relates to the detection of PAMG-1 in the vagina using anti-PAMG-1 antibodies.Type: GrantFiled: August 12, 2003Date of Patent: May 4, 2010Assignee: N-Dia, Inc.Inventors: Boris Fuks, Dmitrii D. Petrunin, Evgeny I. Zaraisky, Marina N. Boltovskaya, Svetlana V. Nazimova, Nelly A. Starosvetskaya, Alexandr Konstantinov, Margarita I. Marshiskaia
-
Patent number: 7704497Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.Type: GrantFiled: January 3, 2007Date of Patent: April 27, 2010Assignees: MedImmune, LLC, Board of Regents, The University of Texas SystemInventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward
-
Patent number: 7704729Abstract: Disclosed is a testing device and methods for the identification of an analyte of interest in a sample. In a preferred embodiment, the testing device includes a front panel having at least one sample application aperture; a rear panel having at least one solvent application aperture; a sample collection matrix disposed between the rear panel and the front panel, the sample collection matrix being in communication with the sample and solvent application apertures of the front and rear panels; and at least one insertable test strip containing a reagent enabling detection of the analyte of interest.Type: GrantFiled: May 12, 2008Date of Patent: April 27, 2010Assignee: Enterix, Inc.Inventor: Howard Milne Chandler
-
Patent number: 7700316Abstract: The invention is a CD109 nucleic acid molecule and its corresponding polypeptide. The invention also includes biologically functional equivalent nucleic acid molecules and polypeptides. The invention also relates to methods of using these nucleic acid sequences and polypeptides in medical diagnosis and treatment and in drug screening.Type: GrantFiled: March 7, 2002Date of Patent: April 20, 2010Inventors: Andre Schuh, D. Robert Sutherland
-
Patent number: 7700373Abstract: The present invention relates to an apparatus for use in an assay comprising: (a) at least one first receptacle comprising a fluid inlet and a fluid outlet, (b) a porous membrane, and (c) at least one analyte-specific binding agent, characterised in that said at least one analyte-specific binding agent is immobilised on the underside of said porous membrane relative to the fluid inlet; and to methods of performing said assay.Type: GrantFiled: May 21, 2004Date of Patent: April 20, 2010Assignee: Nalia Systems Ltd.Inventors: Jeffrey D. McBride, Francis Guy Gabriel, Peter J. Delves, John L. A. Fordham, Ian A. Cree, Keith Rawson
-
Patent number: 7700099Abstract: The present invention relates to a non-immunostimulatory antibody which lacks antibody-dependent cell-mediated cytotoxicity, Fc gamma receptor binding and complement-mediated cytotoxicity. In some embodiments, the antibody contains a modified immunoglobulin G2 (IgG2) Fc region with at least one substitution in the B/C loop, FcRn binding domain, and the F/G loop. The antibody of the invention is useful in the preparation of therapeutic antibodies and pharmaceutical compositions and kits containing the same.Type: GrantFiled: October 17, 2006Date of Patent: April 20, 2010Assignee: Merck & Co., Inc.Inventor: William R. Strohl
-
Patent number: 7691632Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. The present invention comprises antibodies directed to such CCR-proteins. The present invention is directed to a kit for detecting the level of cyclin-dependent kinase inhibitor p16 gene expression comprising antibodies directed to a p16 protein.Type: GrantFiled: August 20, 2008Date of Patent: April 6, 2010Assignee: Cold Spring Harbor LaboratoryInventors: David H. Beach, Douglas J. Demetrick, Manuel Serrano, Gregory J. Hannon
-
Patent number: 7691994Abstract: Compositions and methods for the assessment of T cell receptor variable subunits. The present invention provides nucleotide sequences for the evaluation of the expression of TCRV families. These nucleotides sequences were obtained through a bioinformatic investigation of the nucleotide sequences for TCRV? and TCRV? families. The nucleotide sequences of the present invention uniquely recognize each and every subfamily and allelic member of a particular TCRV family, while at the same time not recognizing the members of any other TCRV family. This unique expression recognition profile of the nucleotide sequences of the present invention provides great utility for the assessment of TCR families in a clinical setting, such as through polymerase chain reactions, gene chip technology, and direct electrophoretic measurement of DNA or RNA.Type: GrantFiled: July 2, 2003Date of Patent: April 6, 2010Inventors: Jamie L. Brewer, Solveig G. Ericson
-
Patent number: 7691595Abstract: Methods for quantitatively measuring the amount of an analyte of interest in a fluid sample, and kits useful in the methods, are disclosed. The methods involve providing a solid phase apparatus comprising a membrane having an application point, a sample capture zone, and a control capture zone, where the sample capture region is between the application point and the control capture zone; and providing a sample collection apparatus comprising a population of analyte binding particles or a population of analyte coated particles. In the assays, a fluid sample is introduced into the sample collection apparatus, and the resultant mixture is applied to the application point of the membrane. The fluid allows transport components of the assay by capillary action to and through the sample capture zone and subsequently to and through the control capture zone. The amount of analyte in the fluid sample is related (e.g.Type: GrantFiled: November 21, 2006Date of Patent: April 6, 2010Assignee: Response Biomedical CorporationInventor: Whalley K. Fong
-
Patent number: 7678373Abstract: The invention provides anti-FGF19 antibodies, and compositions comprising and methods of using these antibodies, methods using anti-FGF19 antibodies, and methods comprising detection of FGF19 and/or FGFR4.Type: GrantFiled: February 9, 2007Date of Patent: March 16, 2010Assignee: Genentech, Inc.Inventors: Luc Desnoyers, Dorothy French
-
Patent number: 7674616Abstract: Test strips designed to prevent or reduce false results when measuring the condition of a sample are provided. The test strips can be used for analysis of samples by methods including electrical and optical measurements. The reagent test strips and methods are particularly suited for use in the detection of blood coagulation.Type: GrantFiled: September 14, 2006Date of Patent: March 9, 2010Assignee: Hemosense, Inc.Inventors: W. Edward Farnam, III, Maria C. Navarro
-
Patent number: 7670789Abstract: A method is provided for diagnosing appendicitis in a patient that includes identifying at least one symptom of appendicitis in the patient and identifying the presence of at least one molecule differentially associated with appendicitis in a fluid or tissue sample of said patient. MRP-8/14 and haptoglobin are examples of molecules differentially associated with appendicitis. Devices and kits for performing the appendicitis assays of this invention are also provided. In one embodiment, the device is in a flow-through immunoassay format for testing blood samples. Further, methods for screening for molecules differentially associated with appendicitis are provided that include the use of samples from patients being operated on for suspected appendicitis.Type: GrantFiled: February 11, 2009Date of Patent: March 2, 2010Assignee: AspenBio Pharma, Inc.Inventors: Mark A. Colgin, John F. Bealer, Richard G. Donnelly, Diane Newman
-
Patent number: 7670600Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.Type: GrantFiled: April 3, 2006Date of Patent: March 2, 2010Assignees: MedImmine, LLC, Board of Regents, The University of Texas SystemInventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward
-
Patent number: 7670792Abstract: Biomarker proteins that can be used in the diagnosis of early-stage ovarian cancer (OC) are described. The biomarker panels not only permit the distinction of patients with ovarian neoplasia (benign or malignant) from normal subjects, but they also allow the identification of patients with early-stage (stage I/II) ovarian cancer from those patients with benign ovarian tumors or normal individuals. The invention additionally provides methods for detecting and treating various cancers, including cancer of the ovary using OC-related molecules.Type: GrantFiled: July 14, 2005Date of Patent: March 2, 2010Assignee: The Regents of the University of CaliforniaInventors: Robin Farias-Eisner, Srinivasa T. Reddy
-
Patent number: 7667003Abstract: The present invention describes a newly discovered full-length polynucleotide encoding an SH2 domain-containing adapter protein, called human MIST, cloned, isolated and identified from a human spleen cDNA library. Also described are the MIST polypeptide sequence, expression vectors, host cells, agonists, antagonists, antisense molecules, and antibodies related to the polynucleotide and/or polypeptide of the present invention. Novel splice variant forms of human MIST are provided. Methods for screening for modulators, particularly inhibitors, of the MIST protein and use of the human MIST polynucleotide and polypeptide for therapeutics and diagnostics are described.Type: GrantFiled: September 4, 2008Date of Patent: February 23, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Juan J. Perez-Villar, Han Chang, Steven B. Kanner, Gena S. Whitney, Yuli Wu, Wen-Pin Yang
-
Patent number: 7666616Abstract: The present invention relates to genetic reporters. Specifically, the present invention is directed to a modified gene encoding a luciferase for high level expression in an organism with a bias for cytosine (C) or guanine (G) in the third position of the codon.Type: GrantFiled: September 30, 2005Date of Patent: February 23, 2010Assignees: Trustees of Dartmouth College, Regents of the University of MinnesotaInventors: Jay C. Dunlap, Jennifer Loros, Arun Mehra, Van D. Gooch
-
Patent number: 7662590Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 19, 2006Date of Patent: February 16, 2010Assignee: ZymoGenetics, LLCInventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Patent number: 7662606Abstract: The present invention relates to the cloning and expression of a novel ?-agarase gene, agaB1, and a novel ?-agarase, AgaB1, encoded from the gene. The present invention also provides a method for producing the ?-agarase, and the utilization of the ?-agarase.Type: GrantFiled: October 1, 2008Date of Patent: February 16, 2010Assignee: Food Industry Research & Development InstituteInventors: Shu-Shan Liang, Yi-Hong Chen, Li-Ling Liaw
-
Patent number: 7662589Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 18, 2006Date of Patent: February 16, 2010Assignee: ZymoGenetics, LLCInventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Patent number: 7659086Abstract: Methods for quantitatively measuring the amount of an analyte of interest in a fluid sample, and kits useful in the methods, are disclosed. The methods comprise sandwich assays, and utilize an internal calibration reaction that closely mimics the reaction of test particles by the use of a two-step reaction.Type: GrantFiled: May 22, 2007Date of Patent: February 9, 2010Assignee: Response Biomedical CorporationInventors: Paul C. Harris, Whalley K. Fong, Lynn Cloney
-
Patent number: 7659055Abstract: A fragment of a nucleic acid specific to mycobacteria of M. tuberculosis complex having a nucleotide sequence of SEQ ID No: 1 and SEQ ID No: 2 and their complimentary sequences.Type: GrantFiled: February 28, 2002Date of Patent: February 9, 2010Assignees: Institut Pasteur de Lille, Institut National de la Sante et de la Recherche MedicaleInventors: Juana Magdalena, Philip Supply, Camille Locht
-
Patent number: 7659107Abstract: A rapid immunochromatographic assay system is provided for measuring the amount of glycated albumin in a blood sample relative to the total level of albumin in the sample. The assay system is comprised of a disposable cassette that contains the test strips and testing reagents, and a measurement device that automatically reads, calculates and displays the test results over a period of time. The test cassette contains two test strips that are used to measure glycated albumin and total albumin respectively. The strips are contiguous beneath the single sample application well so that the same sample is tested simultaneously by both test strips. Part of the sample will migrate thru the glycated albumin test strip where it will react with the glycated albumin test reagents to yield a glycated albumin result, while part of the sample will migrate thru the total albumin test strip where it will react with the total albumin test reagents to yield a total albumin result.Type: GrantFiled: September 22, 2004Date of Patent: February 9, 2010Assignee: Epinex Diagnostics, Inc.Inventors: Henry J. Smith, Asad Zaidi
-
Patent number: 7655416Abstract: The present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for diagnosing the risk of suffering from a cardiovascular complication, particularly heart disease or acute coronary syndrome, as a consequence of cardiotoxic medication, in particular chemotherapeutics, including anthracyclines. In particular, the invention relates to a method for diagnosing the risk of a patient who is going to receive cardiotoxic medication of suffering from a cardiovascular complication as a consequence of the cardiotoxic medication, comprising the steps of (a) taking a body fluid or tissue sample, and (b) measuring, preferably in vitro, the level of a cardiac hormone. Preferred cardiac hormones in the context of the present invention are ANP, NT-proANP, BNP, and NT-proBNP.Type: GrantFiled: December 13, 2006Date of Patent: February 2, 2010Assignee: Roche Diagnostics Operations, Inc.Inventors: Georg Hess, Andrea Horsch
-
Patent number: 7648965Abstract: A method of inducing bone formation in a subject in need of such inducement comprises the steps of mechanically inducing an increase in osteoblast activity in the subject and elevating blood concentration of at least one bone anabolic agent in the subject. The method steps may be performed in any order, but in sufficient time proximity that the elevated concentration of the anabolic agent and the mechanically induced increase in osteoblast activity overlaps. The method may additionally comprise providing the subject with an elevated blood concentration of at least one antiresorptive agent, wherein the elevated concentration is sufficient to prevent resorption of new bone growth produced due to the osteoblast activity. Use of the method permits targeting of specific bones of the subject for bone production and preservation, faster bone production and earlier discontinuation of bone anabolic pharmaceuticals. Kits adapted for performing the method are provided.Type: GrantFiled: November 7, 2005Date of Patent: January 19, 2010Assignees: Unigene Laboratories Inc., Yale UniversityInventors: Agnès Vignery, Nozer M. Mehta, James P. Gilligan
-
Patent number: 7645608Abstract: A device for storing, rehydrating, transferring, and streaking a stored freeze dried specimen comprises a three piece construction including a collection vial used to store a freeze dried specimen, a capsule including a reservoir with hydrating fluid retained by a frangible membrane, and an adapter fluidly linking the capsule to the collection vial. The adapter is configured to fluidly link to the capsule to the collection vial via leak-proof couplings to create a closed system of specimen, hydrating fluid, and a small quantity of trapped air. The fluid communication between the vial and the capsule is accomplished through the adapter via an internal lumen longitudinally traversing the adapter. The adapter and capsule combination can also serve as a transfer pipette once the hydration operation is complete to withdraw the specimen from the collection vial and transfer the specimen to a petri dish or other culture medium.Type: GrantFiled: August 15, 2005Date of Patent: January 12, 2010Assignee: PML Microbiologicals, Inc.Inventor: Nathan Greene
-
Patent number: 7638305Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 18, 2006Date of Patent: December 29, 2009Assignee: ZymoGenetics, LLCInventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Patent number: 7638125Abstract: The invention relates to pharmaceutical compositions comprising different molecules, preferably monoclonal antibodies, each comprising epitopes that bind simultaneously to different sites within the same ErbB receptor domain, preferably the ErbB1 receptor domain. The preferred antibodies according to this invention are MAb 425 and MAb 225 each in its murine, chimeric and humanized version. The invention relates to the use and methods for an improved treatment of preferably tumors by means of said compositions.Type: GrantFiled: October 9, 2003Date of Patent: December 29, 2009Assignee: Merck Patent GmbHInventors: Hans-Georg Kreysch, Juergen Schmidt
-
Patent number: 7638335Abstract: The present invention provides an antihuman TNF-? antibody activity lowering inhibitor comprising a protein source(s) and/or carbohydrate source(s), in the treatment of inflammatory bowel syndrome with repeated administration of anti-TNF-? antibody; and a kit preparation wherein a freeze-dried antihuman TNF-? antibody and the activity lowering inhibitor in the above repeated administration of the anti-TNF-? antibody are separately contained in a plastic container so that they can communicate with each other. According to the present invention, in the drug therapy to the patients with inflammatory bowel syndrome, therapeutic agents which inhibit the inflammation for long periods without accompanying serious side effects can be provided.Type: GrantFiled: September 1, 2006Date of Patent: December 29, 2009Assignee: AJINOMOTO Co., Inc.Inventor: Takayuki Matsumoto
-
Patent number: 7632500Abstract: In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade and methods of detecting an HMGB polypeptide in a sample.Type: GrantFiled: September 20, 2007Date of Patent: December 15, 2009Assignee: Cornerstone Therapeutics, Inc.Inventors: Walter Newman, Shixin Qin, Theresa L. O'Keefe, Robert A. Obar
-
Patent number: 7629178Abstract: An analytical test device incorporating a dry porous carrier to which a liquid sample, eg. urine, suspected of containing an analyte such as HCG or LH can be applied indirectly, the device also incorporating a labelled specific binding reagent which is freely mobile in the porous carrier when in the moist state, and an unlabelled specific binding reagent which is permanently immobilized in a detection zone on the carrier material, the labelled and unlabelled specific binding reagents being capable of participating in either a sandwich reaction or a competition reacts on in the presence of the analyte, in which prior to the application to the device of a liquid sample suspected of containing the analyte, the labelled specific binding reagent is retained in the dry state in a macroporous body, eg.Type: GrantFiled: October 25, 2007Date of Patent: December 8, 2009Assignee: Inverness Medical Switzerland GmbHInventors: Paul James Davis, Michael Evans Prior, Keith May
-
Patent number: 7629180Abstract: A diagnostic and testing apparatus and related methods for the use of the same are disclosed which derive and use antibodies to equine albumin and equine hemoglobin in testing apparatus, kits, and methods for detecting and localizing gastric and colonic ulcers or bleeding in horses. Fecal droppings from a horse to be tested are placed in a container together with a buffered liquid solution and mixed thoroughly, following which several drops of liquid from the container are placed into a test kit. Visual markers in the test kits signify the detection of the indicators equine hemoglobin and equine albumin, which are respectively indicative of the presence of gastric and/or colonic ulcers or bleeding.Type: GrantFiled: November 28, 2006Date of Patent: December 8, 2009Assignee: Freedom Health, LLCInventors: Franklin L. Pellegrini, Scott D. Carter
-
Patent number: 7628986Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.Type: GrantFiled: June 25, 2004Date of Patent: December 8, 2009Assignee: Amgen Fremont Inc.Inventors: Richard Weber, Xiao Feng, Orit Foord, Larry Green, Jean M. Gudas, Bruce Keyt, Ying Liu, Palaniswami Rathanaswami, Robert Raya, Xiao Dong Yang, Jose Corvalan, Ian Foltz, Xiao-Chi Jia, Jaspal S. Kang, Chadwick T. King, Scott L. Klakamp, Qiaojuan Jane Su
-
Patent number: 7629149Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 18, 2006Date of Patent: December 8, 2009Assignee: ZymoGenetics, LLCInventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Patent number: 7629148Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 18, 2006Date of Patent: December 8, 2009Assignee: ZymoGenetics, LLCInventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Patent number: 7625763Abstract: A rapid diagnostic test system includes a lateral-flow strip for performing a binding assay. The lateral-flow strip contains a binding agent having a deposition density that varies periodically along at least a portion of the lateral-flow strip. The test system further includes an imaging system that is used to capture an image of the portion of the lateral-flow strip.Type: GrantFiled: September 11, 2006Date of Patent: December 1, 2009Assignee: Alverix, Inc.Inventor: George Panotopoulos
-
Patent number: 7622560Abstract: The present invention relates to a CD43 epitope expressed on human acute leukemia and lymphoblastic lymphoma cells and its use. More particularly, the present invention relates to a CD43 epitope expressed on human acute leukemia, lymphoblastic lymphoma cells, but not on mature hematopoietic cells, hematopoietic stem cells and non-hematopoietic cells, and to its diagnostic and therapeutic application on acute leukemia and lymphoblastic lymphoma.Type: GrantFiled: December 20, 2005Date of Patent: November 24, 2009Assignee: Dinona Inc.Inventors: Seong-Hoe Park, Kyeong-Cheon Jung, Eun-Young Choi, Seong-Pyo Park
-
Patent number: 7608423Abstract: This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in eukaryotic cells. The components include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNAs/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in eukaryotic cells are also provided.Type: GrantFiled: February 22, 2007Date of Patent: October 27, 2009Assignee: The Scripps Research InstituteInventors: Jason W. Chin, T. Ashton Cropp, J. Christopher Anderson, Peter G. Schultz
-
Patent number: 7608428Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 18, 2006Date of Patent: October 27, 2009Assignee: ZymoGenetics, LLCInventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Patent number: 7608427Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 17, 2006Date of Patent: October 27, 2009Assignee: ZymoGenetics, LLCInventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Patent number: 7601498Abstract: Methods of using dyes and associated technology are provided. A dye, such as a monomeric dye or a dimeric dye, may be used in a nucleic acid gel staining application and/or a nucleic acid detection application. Such a dye and a salt that comprises an anion that is associated with a strong acid and a cation that is associated with a strong base may be used in such an application. A dimeric dye, such as a dimeric dye capable of forming a hairpin-like structure, may be used to stain and/or detect nucleic acids via a release-on-demand mechanism. A dimeric dye having low background fluorescence in the absence of nucleic acids and high fluorescence in the presence of nucleic acids, upon binding therewith, may be used to stain and/or detect nucleic acids.Type: GrantFiled: March 16, 2006Date of Patent: October 13, 2009Assignee: Biotium, Inc.Inventors: Fei Mao, Wai-Yee Leung
-
Patent number: 7598090Abstract: A biosensor is provided with an area in which a reagent having bleaching action is carried in a state where it can be dissolved, at least in a part of a sample application area to which an inspection target solution is applied or the downstream of the sample application area in the direction of the inspection target solution permeating, in a development layer. In the so-constituted biosensor, a colored component in the inspection target solution can be faded by the bleaching reagent, so that the color in parts other than a reactive area is reduced in consequence, whereby a visual judgment is possible and a more accurate measurement result in which a reading error by a measuring device is extremely suppressed can be obtained.Type: GrantFiled: July 24, 2006Date of Patent: October 6, 2009Assignee: Matsushita Electric Industrial Co., Ltd.Inventors: Mie Takahashi, Masataka Nadaoka, Hirotaka Tanaka, Fumihisa Kitawaki
-
Patent number: 7597888Abstract: The invention provides isolated nucleic acid molecules and polypeptide molecules that encode glycoprotein VI, a platelet membrane glycoprotein that is involved platelet-collagen interactions. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: June 29, 2006Date of Patent: October 6, 2009Assignee: Millennium Pharmaceuticals, Inc.Inventors: Davinder Singh Gill, Ming Diana Qian
-
Patent number: 7595174Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 17, 2006Date of Patent: September 29, 2009Assignee: ZymoGenetics, LLCInventors: Lowell J. Brady, Kevin M. Klucher, Chung-leung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Patent number: 7588918Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 17, 2006Date of Patent: September 15, 2009Assignee: ZymoGenetics, LLCInventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Patent number: 7588930Abstract: The present invention includes compositions, methods and kits for enhancing the immunogenicity of an antigen via fusion to a Listerial protein. The present invention further encompasses Listeria vaccine strains for enhancing the immunogenicity of an antigen.Type: GrantFiled: April 30, 2004Date of Patent: September 15, 2009Assignee: The Trustees of the University of PennsylvaniaInventors: Yvonne Paterson, Christian Peters, George Gunn
-
Patent number: 7588919Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 17, 2006Date of Patent: September 15, 2009Assignee: ZymoGenetics, LLCInventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Patent number: 7582450Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.Type: GrantFiled: October 17, 2006Date of Patent: September 1, 2009Assignee: ZymoGenetics, LLCInventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
-
Patent number: 7579195Abstract: The present invention is to provide a simple membrane assay method for detecting or quantitating an analyte in a specimen sample using an assay device equipped with a membrane bound with a capture-substance to capture the analyte, comprising the steps of filtering a specimen sample using a filter, dropping the filtrate onto said membrane and detecting the presence of the analyte in said specimen sample, as well as a simple membrane assay kit for detecting the presence of an analyte in a specimen sample, comprising (1) a filter tube, and (2) an assay device equipped with a membrane bound with a capture-substance to capture the analyte. The method or the kit can decrease the occurrence of false positivity and can provide a highly accurate detection of the analyte such as pathogen and antibody in a specimen collected in a medical scene or by an individual.Type: GrantFiled: June 21, 2006Date of Patent: August 25, 2009Assignee: Denka Seiken Co., LtdInventors: Hideharu Shimizu, Takeshi Watanabe, Kazuyuki Takizawa, Junji Matsuda, Toshinori Sato
-
Patent number: 7579453Abstract: Identified herein are different forms of bitter receptor genes that occur in different humans. These alleles are generated by numerous coding single nucleotide polymorphisms (cSNP's) that occur within the members of the T2R gene family. Some SNP's cause amino acid substitutions, while others introduce chain termination codons, rendering the allele non-functional. Differences in these genes are believed to have a large effect on those individuals' sense of bitter taste, such that these individuals perceive the taste of bitter substances differently than the rest of the population. The ability to assay this allelic information is useful in the development of flavorings and flavor enhancers, as it can be used to define large groups and populations who perceive bitter tastes differently. This in turn allows the taste preferences of these groups to be addressed at the molecular level for the first time.Type: GrantFiled: June 18, 2004Date of Patent: August 25, 2009Assignee: The United States of America as represented by the Secretary of the Dapartment of Health and Human ServicesInventors: Dennis Drayna, Un-Kyung Kim
-
Patent number: 7575915Abstract: A biosensor is provided with a development layer for developing an inspection target solution, that has a reagent immobilization part where an antibody for a measurement target in the inspection target solution is immobilized and a reagent holding part which marks in a dry state and holds an antibody which can be eluted by development of the inspection target solution in parts of the development layer. The biosensor measures a bonding amount of the marker reagent bonded to the reagent immobilization part, thereby qualitatively or quantitatively measuring components to be measured in the inspection target solution, and is further provided with a space forming material that forms a cavity part, which is a space into which the inspection target solution flows, between the development layer for developing the inspection target solution and the space forming material.Type: GrantFiled: May 25, 2001Date of Patent: August 18, 2009Assignee: Panasonic CorporationInventors: Masataka Nadaoka, Mie Takahashi, Hirotaka Tanaka, Fumihisa Kitawaki